RxDoctor Payments Data

Numan Rashid, MD

Critical Care Medicine · Saratoga Springs, NYNPI 1316106818

Payments from drug & device makers

$3,815in general payments, 2019–2025

Across 123 payments — averaging $31.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$902
  • Sanofi$798
  • AstraZeneca$619
  • Actelion Pharmaceuticals US, Inc.$351
  • Boehringer Ingelheim$222
  • CSL Behring$172
  • plus $752 from 12 others

What the payments were for

  • Food & beverage$3,62395%
  • Education$1925%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,815 in reported general payments places this provider in the 85th percentile of 442 critical care medicine providers in New York.

See all critical care medicine providers in New York

Medicare billing

Part B allowed, 2024
$122,296
Medicare patients
534
Services billed
1,510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter794$794,192
Breztri AerosphereBudesonide/Glycopyr/Formoterol234$213,690
OfevNintedanib Esylate13$83,710
Breo ElliptaFluticasone/Vilanterol108$81,987
Dupixent PenDupilumab17$72,933
Dupixent SyringeDupilumab20$72,928
Spiriva RespimatTiotropium Bromide51$47,092
XolairOmalizumab20$41,650
Incruse ElliptaUmeclidinium Bromide58$37,365
EliquisApixaban25$27,937
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr31$23,836
XareltoRivaroxaban12$19,696
Albuterol Sulfate HfaAlbuterol Sulfate404$18,106
SymbicortBudesonide/Formoterol Fumarate32$11,286
Fluticasone-SalmeterolFluticasone Propion/Salmeterol42$8,629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$902$937,379991 claims
AstraZenecaBreztri Aerosphere, Symbicort$619$224,976266 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$222$139,32176 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 442 critical care medicine providers in New York.

Other critical care medicine in Saratoga Springs

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →